title: Neoadjuvant chemotherapy and targeted therapy in breast cancer: past, present, and future.
abstract: Traditionally, neoadjuvant treatment for breast cancer was preserved for locally advanced and inflammatory disease, converting an inoperable to a surgical resectable cancer. In recent years, neoadjuvant therapy has become an accepted treatment option also for lower tumor stages in order to increase the rate of breast conserving therapy and to reduce the extent of surgery. Furthermore, treatment response can be monitored, and therefore, patient compliance may be increased. Neoadjuvant trials, additionally, offer the opportunity to evaluate new treatment options in a faster way and with fewer patients than large adjuvant trials. Compared to the metastatic setting, the issue of acquired resistance and pretreatments, which may distort treatment efficacy, can be avoided. New trial designs like window-of-opportunity trials or postneoadjuvant trials provide the chance to identify tumor sensitivity or to overcome tumor resistance in early tumor stages. In particular, in HER2-positive breast cancer, the neoadjuvant approach yielded great successes. The dual HER2 blockade with trastuzumab and pertuzumab recently showed the highest pCR rates ever reported. Many new drugs are in clinical testing with the aim to further increase pCR rates. Whether this endpoint really represents a surrogate for long-term outcome is not answered yet and will be discussed in this review.
authors.affiliation: 3rd Medical Department with Hematology, Medical Oncology, Hemostaseology, Rheumatology and Infectious Diseases, Oncologic Center, Laboratory of Immunological and Molecular Cancer Research, Paracelsus Medical University, Müllner Hauptstraße 48, 5020 Salzburg, Austria.
authors.forename: Simon P
authors.initials: SP
authors.lastname: Gampenrieder
authors.forename: Gabriel
authors.initials: G
authors.lastname: Rinnerthaler
authors.forename: Richard
authors.initials: R
authors.lastname: Greil
references.citation: J Clin Oncol. 2009 Jun 20;27(18):2938-45
references.pmid: 19364964
references.citation: Lancet Oncol. 2012 Feb;13(2):135-44
references.pmid: 22257523
references.citation: J Clin Oncol. 2005 Jun 1;23(16):3676-85
references.pmid: 15738535
references.citation: J Clin Oncol. 2011 Jun 1;29(16):2150-7
references.pmid: 21519019
references.citation: Ann Oncol. 1998 Nov;9(11):1179-84
references.pmid: 9862047
references.citation: Clin Breast Cancer. 2002 Oct;3 Suppl 2:S69-74
references.pmid: 12435290
references.citation: J Clin Oncol. 2012 Jun 1;30(16):1989-95
references.pmid: 22493419
references.citation: Breast Cancer Res Treat. 2008 Nov;112(2):309-16
references.pmid: 18080748
references.citation: Breast Cancer Res Treat. 1999 Nov;58(2):151-6
references.pmid: 10674880
references.citation: J Natl Cancer Inst. 2005 Feb 2;97(3):188-94
references.pmid: 15687361
references.citation: Breast Cancer Res Treat. 2008 Nov;112(1):203-13
references.pmid: 18158620
references.citation: J Natl Cancer Inst. 2008 Apr 16;100(8):552-62
references.pmid: 18398094
references.citation: J Clin Oncol. 2010 Apr 20;28(12):2015-23
references.pmid: 20308671
references.citation: J Clin Oncol. 2001 Nov 15;19(22):4224-37
references.pmid: 11709566
references.citation: J Clin Oncol. 2002 Mar 15;20(6):1456-66
references.pmid: 11896092
references.citation: J Clin Oncol. 2012 May 20;30(15):1796-804
references.pmid: 22508812
references.citation: Ann Oncol. 1991 May;2(5):347-54
references.pmid: 1954179
references.citation: Ann Oncol. 2011 Sep;22(9):1988-1998
references.pmid: 21385882
references.citation: J Clin Oncol. 2004 Dec 15;22(24):4958-65
references.pmid: 15611510
references.citation: J Clin Oncol. 1998 Aug;16(8):2672-85
references.pmid: 9704717
references.citation: Eur J Cancer. 1994;30A(5):645-52
references.pmid: 8080680
references.citation: Ann Oncol. 2005 Jan;16(1):56-63
references.pmid: 15598939
references.citation: J Natl Cancer Inst. 2007 Jan 17;99(2):167-70
references.pmid: 17228000
references.citation: Ann Oncol. 2004 May;15(5):751-8
references.pmid: 15111342
references.citation: Cochrane Database Syst Rev. 2007 Apr 18;(2):CD005002
references.pmid: 17443564
references.citation: J Clin Oncol. 2006 May 1;24(13):2019-27
references.pmid: 16606972
references.citation: J Natl Cancer Inst. 2008 Apr 16;100(8):542-51
references.pmid: 18398097
references.citation: Oncologist. 2011;16(11):1527-34
references.pmid: 22042783
references.citation: N Engl J Med. 2012 Jan 26;366(4):299-309
references.pmid: 22276820
references.citation: J Clin Oncol. 2005 Apr 20;23(12):2676-85
references.pmid: 15837982
references.citation: J Clin Oncol. 2011 Sep 1;29(25):3351-7
references.pmid: 21788566
references.citation: Lancet Oncol. 2012 Jan;13(1):25-32
references.pmid: 22153890
references.citation: J Clin Oncol. 1995 Mar;13(3):547-52
references.pmid: 7884414
references.citation: J Clin Oncol. 2011 Mar 10;29(8):1014-21
references.pmid: 21220618
references.citation: Ann Oncol. 2005 Sep;16(9):1435-41
references.pmid: 15946977
references.citation: Lancet. 2010 Jan 30;375(9712):377-84
references.pmid: 20113825
references.citation: Lancet. 2012 Feb 18;379(9816):633-40
references.pmid: 22257673
references.citation: J Clin Oncol. 2003 Nov 15;21(22):4165-74
references.pmid: 14559892
references.citation: J Clin Oncol. 2005 May 1;23(13):2988-95
references.pmid: 15860854
references.citation: Breast Cancer Res Treat. 2012 Oct;135(3):821-30
references.pmid: 22933030
references.citation: Cancer. 2008 Jul 15;113(2):238-46
references.pmid: 18470908
references.citation: J Clin Oncol. 2007 Jul 1;25(19):2650-5
references.pmid: 17602071
references.citation: J Natl Cancer Inst Monogr. 2001;(30):96-102
references.pmid: 11773300
references.citation: J Clin Oncol. 2003 Apr 1;21(7):1195-204
references.pmid: 12663705
references.citation: Breast Cancer Res Treat. 2011 Jan;125(1):145-56
references.pmid: 21042932
references.citation: Ann Oncol. 2011 Sep;22(9):1999-2006
references.pmid: 21382868
references.citation: Ann Oncol. 1999 Jan;10(1):47-52
references.pmid: 10076721
references.citation: J Clin Oncol. 2010 Apr 20;28(12):2024-31
references.pmid: 20308670
references.citation: N Engl J Med. 2012 Jan 26;366(4):310-20
references.pmid: 22276821
references.citation: J Clin Oncol. 2008 Feb 10;26(5):778-85
references.pmid: 18258986